Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
Alternative names
aflibercept (zaltrap) (4 trials)
ranibizumab (lucentis) (4 trials)
ico-007 (1 trial)
Diabetic Retinopathy (Phase 2)
Edema (Phase 2)
Macular Degeneration (Phase 3)
Macular Edema (Phase 2)
Retinal Diseases (Phase 2)
Retinal Vein Occlusion (Phase 4)
Trials (8 total)
Trial APIs (3 total)